Hebei Medical University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1894-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.hebmu.edu.cn
Gingiva Mesenchymal Stem Cells Treatment of Chronic Periodontitis
Phase 1
- Conditions
- Periodontitis
- Interventions
- Biological: GMSCs and collagen scaffoldsProcedure: Open flap debridementBiological: Collagen scaffolds
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2017-05-03
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 30
- Registration Number
- NCT03137979
- Locations
- 🇨🇳
the First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Aplastic Anemia
Phase 1
- Conditions
- Aplastic Anemia
- Interventions
- Biological: mesenchymal stem cells
- First Posted Date
- 2017-02-16
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 10
- Registration Number
- NCT03055078
- Locations
- 🇨🇳
the First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells
- First Posted Date
- 2015-07-29
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 48
- Registration Number
- NCT02510469
- Locations
- 🇨🇳
Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer
- First Posted Date
- 2015-07-28
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 48
- Registration Number
- NCT02509806
- Locations
- 🇨🇳
Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis
Phase 4
- Conditions
- HER-2 Positive Gastric CancerLiver Metastasis
- Interventions
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 60
- Registration Number
- NCT02380131
- Locations
- 🇨🇳
Department of Internal Medicine-Oncology, Shijiazhuang, Hebei, China
Long-term Prednisone Use for End-stage Heart Failure
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 90
- Registration Number
- NCT02282683
- Locations
- 🇨🇳
The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Prednisone for Heart Failure Patients With Hyperuricemia
Phase 2
Completed
- Conditions
- Heart Failure, Hyperuricemia
- Interventions
- First Posted Date
- 2014-05-02
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 205
- Registration Number
- NCT02129764
Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis
Phase 4
- Conditions
- Liver MetastasisGastric Cancer
- Interventions
- Drug: Oxaliplatin;CapecitabineDrug: Oxaliplatin;Capecitabine;Bevacizumab
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2013-10-14
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 60
- Registration Number
- NCT01962376
- Locations
- 🇨🇳
Department of Internal Medicine-Oncology, Shijiazhuang, Hebei, China
Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Hypoxic Ischemic Encephalopathy
Phase 1
- Conditions
- Hypoxic Ischemic Encephalopathy
- Interventions
- Biological: mesenchymal stem cells
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2013-10-14
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 10
- Registration Number
- NCT01962233
- Locations
- 🇨🇳
the First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction
Phase 2
Completed
- Conditions
- Gastroesophageal Junction Adenocarcinoma
- Interventions
- Other: Oxaliplatin; Capecitabine; concurrent radiotherapy
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2022-02-21
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 169
- Registration Number
- NCT01962246
- Locations
- 🇨🇳
Department of General Surgery, Shijiazhuang, Hebei, China